A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Japan Food Research Laboratories

Japan Food Research Laboratories

Table of Contents
Table of Contents

Japan Food Research Laboratories (JFRL) conducts a wide range of non-clinical studies on pharmaceutical drugs, medical devices, and chemical substances in compliance with the GLP standard.

With extensive experience and comprehensive testing facilities, the organization provides contract research services covering safety and toxicity evaluations, as well as storage stability testing, to meet diverse clients’ needs.

Features of JFRL’s Contract Services for Non-Clinical Studies

Comprehensive Toxicity Evaluation System In a Wide Range of Testing Methods

JFRL performs both in vitro and in vivo studies in compliance to GLP standards. Its capabilities include various toxicity evaluations—such as cytotoxicity, mutagenicity, and acute toxicity testing for medical devices, pharmaceutical drugs, and chemical substances. Analytical methods followed by ISO, OECD Test Guidelines, and the Japanese Pharmacopoeia, ensuring full regulatory compliance.

The laboratory also provides flexible study designs tailored to client’s requirements and applicable legal frameworks.

Testing for a Wide Variety of Materials Including Medical Devices and Chemicals

A notable strength of JFRL is its capability to conduct testing across a broad spectrum of materials and products, such as medical devices and their components, foods, pharmaceutical raw materials, and industrial chemicals. By applying multiple international and domestic standards—such as OECD TGs, Medical Device Guidance, and the Japanese Pharmacopoeia—JFRL offers customized testing strategies suited to the intended use and characteristics of each material.

Each test category clearly specifies its applicable scope and required sample quantities, allowing for efficient study planning from the beginning.

Specialized Facilities for Stability Testing

For storage stability studies, JFRL operates their specialized facilities equipped to perform long-term, accelerated, and stress-condition testing. The facilities are supported by an independent power supply and automated alert systems, ensuring prompt responses to any unusual event during the testing period.

Temperature, humidity, and light conditions can be precisely controlled to accommodate diverse storage requirements, with its integrated analytical systems in place for post-storage evaluation. This robust infrastructure enables JFRL to meet a wide range of stability assessment needs.

Example of Disease Models by JFRL

No information on disease models was found on the official website.

Case Example of JFRL’s Non-Clinical Testing

Evaluation of Genotoxicity Using the Ames Test

JFRL conducts reversion mutation tests (Ames tests) for medical devices, chemical substances, and food products.Mutagenicity is assessed following the 1999 Ministry of Health, Labour and Welfare guidelines and medical device guidance.

Tests are typically conducted using 5 g of solid samples or 10 g of liquid samples, with a standard turnaround time of approximately two months. The cost starts from 400,000 yen (excluding tax), and expedited testing is not available. This study design is particularly relevant to applications in the pharmaceutical and chemical sectors.

Reference: https://www.jfrl.or.jp/service/safetytrial

Company Information

Address52-1 Moto Yoyogi-cho, Shibuya-ku, Tokyo, Japan
Tel03-3469-7131
Websitehttps://www.jfrl.or.jp/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services